Lavoisier S.A.S.
14 rue de Provigny
94236 Cachan cedex
FRANCE

Heures d'ouverture 08h30-12h30/13h30-17h30
Tél.: +33 (0)1 47 40 67 00
Fax: +33 (0)1 47 40 67 02


Url canonique : www.lavoisier.fr/livre/genie-pharmaceutique/developability-of-biotherapeutics/kumar/descriptif_3585808
Url courte ou permalien : www.lavoisier.fr/livre/notice.asp?ouvrage=3585808

Developability of Biotherapeutics Computational Approaches

Langue : Anglais

Auteurs :

Couverture de l’ouvrage Developability of Biotherapeutics

Biopharmaceuticals are emerging as frontline medicines to combat several life-threatening and chronic diseases. However, such medicines are expensive to develop and produce on a commercial scale, contributing to rising healthcare costs. Developability of Biotherapeutics: Computational Approaches describes applications of computational and molecular modeling techniques that improve the overall process of discovery and development by removing empiricism.

The concept of developability involves making rational choices at the pre-clinical stages of biopharmaceutical drug development that could positively impact clinical outcomes. The book also addresses a general lack of awareness of the many different contributions that computation can make to biopharmaceutical drug development.

This informative and practical reference is a valuable resource for professionals engaged in industrial research and development, scientists working with regulatory agencies, and pharmacy, medicine, and life science students and educators. It focuses primarily on the developability of monoclonal antibody candidates, but the principles described can also be extended to other modalities such as recombinant proteins, fusion proteins, antibody drug conjugates and vaccines.

The book is organized into two sections. The first discusses principles and applications of computational approaches toward discovering and developing biopharmaceutical drugs. The second presents best practices in developability assessments of early-stage biopharmaceutical drug candidates.

In addition to raising awareness of the promise of computational research, this book also discusses solutions required to improve the success rate of translating biologic drug candidates into products available in the clinic. As such, it is a rich source of information on current principles and practices as well as a starting point for finding innovative applications of computation towards biopharmaceutical drug development.

Principles of biopharmaceutical informatics
. Biopharmaceutical Informatics: Applications of Computation in Biologic Drug Development
. Computational Methods in the Optimization of Biologic Modalities
. Understanding, Predicting, and Mitigating the Impact of Posttranslational Physiochemical Modifications, Including Aggregation, on the Stability of Biopharmaceutical Drug Products
. Preclinical Immunogenicity Risk Assessment of Biotherapeutics
. Application of Mechanistic Pharmacokinetic–Pharmacodynamic Modeling toward the Development of Biologics
. Challenges in High-Concentration Biopharmaceutical Drug Delivery: A Modeling Perspective

Developability practices in the biopharmaceutical industry
. Best Practices in Assessment of Developability in Biopharmaceutical Candidates
. Best Practices in Developability Assessments of Therapeutic Protein Candidates in the Biopharmaceutical Industry
. Best Practices in Assessing the Developability of Biopharmaceutical Candidates
. Developability Assessment Workflows to De-Risk Biopharmaceutical Development
Sandeep Kumar, PhD, is a senior principal scientist at Pfizer, Inc. in the Biotherapeutics Pharmaceutical Sciences group, working on computational modeling and developability risk assessments of a wide variety of biotherapeutic drug candidates, including monoclonal antibodies, antibody-based therapeutics, fusion proteins, vaccines, and antibody–drug conjugates

Satish Kumar Singh, PhD, is a research fellow at Pfizer, Inc. in the Biotherapeutics Pharmaceutical Sciences group, and an adjunct professor of the Department of Physical Pharmaceutical Chemistry at Uppsala University in Sweden. His responsibilities include leading formulation, product, and process development activities for biologics and therapeutic vaccines.

Date de parution :

Ouvrage de 297 p.

Disponible chez l'éditeur (délai d'approvisionnement : 13 jours).

152,79 €

Ajouter au panier

Thème de Developability of Biotherapeutics :

En continuant à naviguer, vous autorisez Lavoisier à déposer des cookies à des fins de mesure d'audience. Pour en savoir plus et paramétrer les cookies, rendez-vous sur la page Confidentialité & Sécurité.
FERMER